New pill trial offers hope for controlling debilitating blood disease
NCT ID NCT07177859
Summary
This study is testing an experimental oral medication called NTQ5082 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disease. It will compare NTQ5082 against an existing standard treatment to see if it's better at raising and maintaining hemoglobin levels, reducing the need for blood transfusions. The main goal is to see if patients can reach healthier hemoglobin levels for a sustained period without receiving any red blood cell transfusions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.